|Intro||Surgeon, CEO & Philanthropist active in the Los Angeles community.|
|Is||Businessperson Surgeon Business executive Professor Educator|
|From||United States of America South Africa|
|Type||Academia Business Healthcare|
|Birth||29 July 1952, Port Elizabeth|
Patrick Soon-Shiong (Chinese: 黃馨祥; pinyin: Huáng Xīnxiáng, [xu̯ɑ̌ŋ ɕín ɕi̯ɑ̌ŋ]; born July 29, 1952) is an American surgeon, entrepreneur, and philanthropist. He is chair of NantWorks, LLC, executive director of the Wireless Health Institute at the University of California at Los Angeles, and an adjunct professor of surgery at UCLA. He is chair of the Chan Soon-Shiong Family Foundation, and chair and CEO of the Chan Soon-Shiong Institute for Advanced Health, National LambdaRail (which ceased to exist in 2014), and the Healthcare Transformation Institute. Soon-Shiong has been a minority owner of the Los Angeles Lakers since 2010. Since 2018, he has been the owner of the Los Angeles Times and The San Diego Union-Tribune. In April 2016, the Los Angeles Times reported him to be one of the highest-paid CEOs for 2015. As of November 2016, Soon-Shiong was estimated by Forbes as having a net worth of US$9 billion, ranking him #47 among US billionaires. As of December 2016, he has 92 US and 138 international patents.
Early life and education
Soon-Shiong was born in Port Elizabeth, South Africa to Chinese immigrant parents who fled from China during the Japanese occupation in World War II. His parents were originally from Toisan in Guangdong province. His ancestral surname is Wong (Huang 黃).
Soon-Shiong graduated 4th out of his class of 189 from the University of Witwatersrand, receiving a bachelor's degree in medicine (MBBCh) at age 23. He completed his medical internship at Johannesburg's General Hospital. He then studied at the University of British Columbia, where he earned a master's degree in 1979, with research awards from the American College of Surgeons, the Royal College of Physicians and Surgeons of Canada, and the American Association of Academic Surgery.
He moved to the United States and began surgical training at University of California, Los Angeles (UCLA), and became a board-certified surgeon in 1984. Soon-Shiong is a Fellow of the Royal College of Surgeons (Canada) and a Fellow of the American College of Surgeons.
Soon-Shiong joined UCLA Medical School in 1983 and served on that faculty until 1991, as a transplant surgeon. Between 1984 and 1987, he served as an associate investigator at the Center for Ulcer Research and Education. Soon-Shiong performed the first whole-pancreas transplant done at UCLA, and he developed and first performed the experimental Type 1 diabetes-treatment known as encapsulated-human-islet transplant, and the "first pig-to-man islet-cell transplant in diabetic patients." After a period in industry, he returned to UCLA in 2009, serving as a professor of microbiology, immunology, molecular genetics and bioengineering until this date. Soon-Shiong served as a visiting professor at Imperial College, London in 2011.
In 1991, Soon-Shiong left UCLA to start a diabetes and cancer biotechnology firm called VivoRx Inc. This led to the founding in 1997 of APP Pharmaceuticals, of which he held 80% of outstanding stock and sold to Fresenius SE for $4.6 billion in July 2008. Soon-Shiong later founded Abraxis BioScience (maker of the drug Abraxane he co-discovered), a company he sold to Celgene in 2010 in cash-and-stock deal, valued at over $3 billion.
Soon-Shiong founded NantHealth in 2007 to provide fiber-optic, cloud-based data infrastructure to share healthcare information. Soon-Shiong went on to found NantWorks in September 2011, whose mission was "to converge ultra-low power semiconductor technology, supercomputing, high performance, secure advanced networks and augmented intelligence to transform how we work, play, and live." In October 2012, Soon-Shiong announced that NantHealth's supercomputer-based system and network were able to analyze the genetic data from a tumor sample in 47 seconds and transfer the data in 18 seconds. The goal of developing this infrastructure and digital technologies was to share genomic information among sequencing centers, medical research hubs and hospitals, and to advance cancer research and big science endeavors such as The Cancer Genome Atlas. In January 2013, he founded another biotech company, NantOmics, to develop cancer drugs based on protein kinase inhibitors. NantOmics and its sister company, NantHealth, were subsidiaries of NantWorks. Soon-Shiong stated that NantWorks' vision for the future of cancer treatment was a convergence of multiple technologies that included diagnostics, supercomputing, network modeling of sharing data on tumor genes and personalized cocktails of cancer drugs in multi-target attacks, to achieve a sustained disease-free state.
In 2010, with Arizona State University and the University of Arizona, Soon-Shiong founded the Healthcare Transformation Institute (HTI), which he dubs a "do-tank". HTI's mission is to promote a paradigm shift in health care in the United States by better integrating the three now separate domains of medical science, health delivery, and healthcare finance. In 2014, Soon-Shiong funded online streaming music service AccuRadio, investing $2.5 million into the first round of funding for America's fastest-growing music webcaster. In July 2015, Soon-Shiong initiated an IPO for NantKwest (formerly ConkWest) that represented the highest value biotech IPO in history, at a market value of $2.6 billion. In April 2016, the Los Angeles Times reported that Soon-Shiong received a pay package in 2015 from NantKwest worth almost $148 Million, making him one of the highest paid CEOs. Soon-Shiong is also a member of the Berggruen Institute's 21st Century Council.
In 2014 Soon-Shiong made a $12 million donation to the University of Utah. An audit three years later found several legal violations. As part of the donation, the university was required to use Soon-Shiong's company for the services required for the research, at a total cost of $10 million. NantHealth set the price for DNA sequencing at $10,000 per sample, while auditors found that other companies charged between $2,900 and $5,000 for the same service. Legal experts referred to it as money laundering, or perhaps a technique to receive tax deductions for an investment in Soon-Shiong's own company.
In early 2016, Soon-Shiong launched the National Immunotherapy Coalition to encourage rival pharmaceutical companies to work together to test combinations of cancer-fighting drugs. He has also met numerous times with former Vice President Joe Biden to discuss more ambitious approaches to fighting cancer, including conducting genomic sequencing of 100,000 patients to create a massive database of potential genetic factors.
In February 2018, the Los Angeles Times reported that Soon-Shiong's investment firm Nant Capital reached a deal to purchase the paper and The San Diego Union-Tribune from Tronc Inc. for "nearly $500 million in cash" as well as the assumption of $90 million in pension obligations. Soon-Shiong, with this acquisition became one of the first Asian-Americans to become a media proprietor through ownership in a major daily newspaper in the United States. The sale closed on June 18, 2018.
In September 2018, his company NantEnergy announced the development of a zinc air battery with a projected cost of $100 per kilowatt-hour (less than one-third the cost of lithium-ion batteries).
He is married to Michele B. Chan, lives in Los Angeles, California, and has two children, daughter Nika and son Luke.